The clinical course of cirrhosis: The importance of multistate models and competing risks analysis

被引:136
|
作者
Jepsen, Peter [1 ,2 ]
Vilstrup, Hendrik [1 ]
Andersen, Per Kragh [3 ]
机构
[1] Aarhus Univ Hosp, Dept Gastroenterol & Hepatol, DK-8000 Aarhus, Denmark
[2] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark
[3] Univ Copenhagen, Inst Publ Hlth, Dept Biostat, Copenhagen, Denmark
关键词
HEPATOCELLULAR-CARCINOMA; SURVIVAL; HISTORY;
D O I
10.1002/hep.27598
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Multistate models are models of disease progression that, for a patient group, define multiple outcome events, each of which may affect the time to develop another outcome event. Multistate models are highly relevant for studies of patients with cirrhosis; both the classical perception of cirrhosis as either compensated or decompensated and the recent, more complex models of cirrhosis progression are multistate models. Therefore, researchers who conduct clinical studies of patients with cirrhosis must realize that most of their research questions assume a multistate disease model. Failure to do so can result in severely biased results and bad clinical decisions. The analyses that can be used to study disease progression in a multistate disease model may be called competing risks analysis, named after the competing risks disease model, which is the simplest multistate disease model. In this review article, we introduce multistate disease models and competing risks analysis and explain why the standard armamentarium of Kaplan-Meier survival estimates and Cox regression sometimes gives bad answers to good questions. We also use real data to answer typical research questions about the course of cirrhosis and illustrate biases resulting from inadequate methods. Finally, we suggest statistical software packages that are helpful and accessible to the clinician-researcher. (Hepatology 2015;62:292-302)
引用
收藏
页码:292 / 302
页数:11
相关论文
共 50 条
  • [1] The Clinical Course of Cirrhosis: The Importance of Multistate Models and Competing Risks Analysis (vol 62, pg 292, 2015)
    Jepsen, Peter
    Vilstrup, Hendrik
    Andersen, Per Kragh
    [J]. HEPATOLOGY, 2017, 66 (01) : 304 - 304
  • [2] Interpretability and importance of functionals in competing risks and multistate models
    Andersen, Per Kragh
    Keiding, Niels
    [J]. STATISTICS IN MEDICINE, 2012, 31 (11-12) : 1074 - 1088
  • [3] Competing Risks and Multistate Models
    Schmoor, Claudia
    Schumacher, Martin
    Finke, Juergen
    Beyersmann, Jan
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (01) : 12 - 21
  • [4] Clinical states of cirrhosis and competing risks
    D'Amico, Gennaro
    Morabito, Alberto
    D'Amico, Mario
    Pasta, Linda
    Malizia, Giuseppe
    Rebora, Paola
    Valsecchi, Maria Grazia
    [J]. JOURNAL OF HEPATOLOGY, 2018, 68 (03) : 563 - 576
  • [5] A note on nonparametric quantile inference for competing risks and more complex multistate models
    Beyersmann, Jan
    Schumacher, Martin
    [J]. BIOMETRIKA, 2008, 95 (04) : 1006 - 1008
  • [6] Analysis of parametric models for competing risks
    Maller, RA
    Zhou, X
    [J]. STATISTICA SINICA, 2002, 12 (03) : 725 - 750
  • [7] Statistical analysis of competing risks models
    Sarhan, Ammar M.
    Hamilton, David C.
    Smith, B.
    [J]. RELIABILITY ENGINEERING & SYSTEM SAFETY, 2010, 95 (09) : 953 - 962
  • [8] The importance of censoring in competing risks analysis of the subdistribution hazard
    Mark W. Donoghoe
    Val Gebski
    [J]. BMC Medical Research Methodology, 17
  • [9] The importance of censoring in competing risks analysis of the subdistribution hazard
    Donoghoe, Mark W.
    Gebski, Val
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2017, 17
  • [10] Competing risks analysis in cancer clinical trials
    Tai, BC
    Machin, D
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, : 35 - 35